子宫内膜不典型增生分子标志物的作用机制及研究进展
Research Progress on the Mechanism of Molecular Markers in Endometrial Atypical Hyperplasia
DOI: 10.12677/acm.2026.1651935, PDF,   
作者: 尹艺达*:北华大学,吉林 吉林;蔡娱飞#:北华大学附属医院,吉林 吉林
关键词: 子宫内膜不典型增生分子标志物研究进展Endometrial Atypical Hyperplasia Molecular Markers Research Progress
摘要: 子宫内膜不典型增生(endometrial atypical hyperplasia, AH)是女性生殖系统常见的病变之一,其本质是子宫内膜出现病理性改变。近年来随着人口老龄化趋势增加、现代人生活习惯转变等因素影响,其发病率逐年升高,且趋于年轻化。AH患者若不及时进行治疗,发展成子宫内膜癌的风险会显著升高。因此早期精准的筛查及诊治是AH患者改善生存质量,提高生存率的重要环节。目前临床上诊断AH的“金标准”主要依赖于组织病理学检查,但侵入性操作带来的并发症风险与取材局限性,使其难以满足大规模人群筛查需求,因此寻求特异的无创性生物学指标来诊断早期AH尤其重要。目前随着科学进步,分子层面的生物学标志物逐渐浮现,因其可以识别早期、低水平的病理改变,故逐渐成为AH辅助诊断的得力助手。本文梳理近年来AH诊断相关分子标志物的研究进展,并对其发病机制、研究现状、临床应用等方面进行分析,为后续研究提供参考。
Abstract: Endometrial atypical hyperplasia (AH) is one of the common lesions in the female reproductive system, characterized by pathological changes in the endometrium. In recent years, influenced by factors such as population aging and changes in modern lifestyle, the incidence of AH has been increasing year by year and tends to be younger. If left untreated, patients with AH face a significantly elevated risk of developing endometrial cancer. Therefore, early and precise screening and diagnosis are crucial for improving the quality of life and survival rate of AH patients. Currently, the “gold standard” for clinical diagnosis of AH mainly relies on histopathological examination. However, the risk of complications and limitations of sampling associated with invasive procedures make it difficult to meet the needs of large-scale population screening. Thus, it is particularly important to seek specific non-invasive biological indicators for the diagnosis of early AH. With scientific advances, molecular-level biological biomarkers have emerged, as they can more subtly explain the core mechanisms of disease occurrence and development, identify early and low-level pathological changes, and provide new directions for clinical early warning and auxiliary diagnosis, gradually becoming a valuable assistant in the auxiliary diagnosis of AH. This article reviews the recent research progress of AH-related molecular markers and analyzes their pathogenesis, research status, and clinical applications, providing a reference for subsequent studies.
文章引用:尹艺达, 蔡娱飞. 子宫内膜不典型增生分子标志物的作用机制及研究进展[J]. 临床医学进展, 2026, 16(5): 1340-1347. https://doi.org/10.12677/acm.2026.1651935

参考文献

[1] 杨晓辉, 李小毛. 发病年龄对子宫内膜癌预后的影响[J]. 广东医学, 2015, 36(7): 1033-1036.
[2] Yen, T., Wang, T., Fader, A.N., Shih, I. and Gaillard, S. (2020) Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 39, 26-35. [Google Scholar] [CrossRef] [PubMed]
[3] Soliman, P.T., Oh, J.C., Schmeler, K.M., Sun, C.C., Slomovitz, B.M., Gershenson, D.M., et al. (2005) Risk Factors for Young Premenopausal Women with Endometrial Cancer. Obstetrics & Gynecology, 105, 575-580. [Google Scholar] [CrossRef] [PubMed]
[4] 杨君, 唐良萏, 王彬. PTEN、P27、TGF-β1在宫颈腺癌组织中的表达及临床意义[J]. 第三军医大学学报, 2009, 31(2): 148-151.
[5] Jing, X., Cheng, W., wang, S., Li, P. and He, L. (2016) Resveratrol Induces Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells via the PTEN-Regulated PI3K/Akt Signaling Pathway. Oncology Reports, 35, 472-478. [Google Scholar] [CrossRef] [PubMed]
[6] Djordjevic, B., Hennessy, B.T., Li, J., Barkoh, B.A., Luthra, R., Mills, G.B., et al. (2012) Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Outperforms Gene Sequencing. Modern Pathology, 25, 699-708. [Google Scholar] [CrossRef] [PubMed]
[7] Baak, J.P.A., van Diermen, B., Steinbakk, A., Janssen, E., Skaland, I., Mutter, G.L., et al. (2005) Lack of PTEN Expression in Endometrial Intraepithelial Neoplasia Is Correlated with Cancer Progression. Human Pathology, 36, 555-561. [Google Scholar] [CrossRef] [PubMed]
[8] 龚燕玲, 江丽娟, 李麟. PTEN和PAX-2蛋白在子宫内膜非典型增生中的表达及其意义[J]. 癌变·畸变·突变, 2025, 37(6): 478-482.
[9] 李少星, 余华, 杨惠欢, 等. 抑癌基因PTEN、P27在子宫内膜癌及癌前病变中的表达及其临床意义[J]. 西部医学, 2021, 33(8): 1215-1219.
[10] 彭继英, 陈耀丽, 李剑, 尹为华, 余光银. PAX2在诊断早期子宫内膜癌及其癌前病变中的应用研究[J]. 中国实用医药, 2019, 14(24): 46-47.
[11] Allison, K.H., Upson, K., Reed, S.D., Jordan, C.D., Newton, K.M., Doherty, J., et al. (2012) PAX2 Loss by Immunohistochemistry Occurs Early and Often in Endometrial Hyperplasia. International Journal of Gynecological Pathology, 31, 151-159. [Google Scholar] [CrossRef] [PubMed]
[12] 朱丽娜, 史雪鸿, 王晓晶, 等. 配对盒基因2在子宫内膜增生性病变中的表达及意义[J]. 中华病理学杂志, 2019, 48(2): 141-143.
[13] 张彤, 沈丹华, 陈云新, 等. PTEN、PAX-2和β-Catenin在Ⅰ型子宫内膜癌及其癌前病变中的表达及意义[J]. 现代妇产科进展, 2014, 23(2): 85-88.
[14] 祁晓莉, 张轶华, 王春艳, 张立英, 刘洪波, 王彦, 卢晓红. PAX-2、PTEN、ER和Ki-67在子宫内膜癌及其癌前病变组织中的表达及意义[J]. 临床和实验医学杂志, 2018, 17(9): 933-937.
[15] Saegusa, M., Hashimura, M., Yoshida, T. and Okayasu, I. (2001) β-Catenin Mutations and Aberrant Nuclear Expression during Endometrial Tumorigenesis. British Journal of Cancer, 84, 209-217. [Google Scholar] [CrossRef] [PubMed]
[16] Aguilar, M., Chen, H., Rivera-Colon, G., Niu, S., Carrick, K., Gwin, K., et al. (2022) Reliable Identification of Endometrial Precancers through Combined Pax2, β-Catenin, and PTEN Immunohistochemistry. American Journal of Surgical Pathology, 46, 404-414. [Google Scholar] [CrossRef] [PubMed]
[17] Lucas, E., Niu, S., Aguilar, M., Molberg, K., Carrick, K., Rivera-Colon, G., et al. (2023) Utility of a PAX2, PTEN, and Β-Catenin Panel in the Diagnosis of Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia in Endometrial Polyps. American Journal of Surgical Pathology, 47, 1019-1026. [Google Scholar] [CrossRef] [PubMed]
[18] 黄雪云, 张丽华, 魏晓莹, 等. PAX-2、β-Catenin及HAND2蛋白在子宫内膜增生症中的表达及其意义[J]. 东南大学学报(医学版), 2017, 36(6): 919-923.
[19] 孟轶婷, 马东林, 李莉, 等. PAX-2和PTEN在子宫内膜病变中的表达及其与子宫内膜上皮内瘤变的相关性[J]. 肿瘤研究与临床, 2017, 29(1): 27-31.
[20] 吕明医, 孙慧婷, 刘慧君, 等. 子宫内膜不典型增生的分子生物学标志物的研究进展[J]. 中国医药导报, 2022, 19(19): 57-60.
[21] Yang, S., Thiel, K.W. and Leslie, K.K. (2011) Progesterone: The Ultimate Endometrial Tumor Suppressor. Trends in Endocrinology & Metabolism, 22, 145-152. [Google Scholar] [CrossRef] [PubMed]
[22] 李琼珊, 杜英. 雌、孕激素受体在子宫内膜增生中的表达及意义[J]. 现代实用医学, 2010, 22(11): 1288-1289.
[23] Arnett-Mansfield, R.L., deFazio, A., Wain, G.V., et al. (2001) Relative Expression of Progesterone Receptors A and B in Endometrioid Cancers of the Endometrium. Cancer Research, 61, 4576-4582.
[24] 要秀娥, 赵敏. ARID1a及性激素受体在子宫内膜增生病变组织中的表达及意义[J]. 实用妇科内分泌杂志(电子版), 2017, 4(1): 78-80+82.
[25] 梁静, 张贵宇, 马本红, 等. 子宫内膜样腺癌组织中microRNA差异表达谱分析[J]. 山东大学学报(医学版), 2011, 49(8): 90-95.